Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population1
Medtronic, a global leader in healthcare technology, today announced...
Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population1
Medtronic, a global leader in healthcare technology, today announced...
August 5-8 event at new location in Boston highlights DVA, drug-eluting tech, eight first-to-podium research presentations, and featuring a cadaver lab.
August 5-8 event at new location in Boston highlights DVA, drug-eluting tech, eight first-to-podium research presentations, and featuring a cadaver lab.
DEEPER REVEAL is a prospective, non-randomized, multicenter study evaluating use of the Spur Peripheral Retrievable Stent System following predilatation in patients with chronic limb-threatening ischemia (CLTI) and below-the-knee (BTK)...
DEEPER REVEAL is a prospective, non-randomized, multicenter study evaluating use of the Spur Peripheral Retrievable Stent System following predilatation in patients with chronic limb-threatening ischemia (CLTI) and below-the-knee (BTK)...
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
“Together with the initial STORM PE results, which demonstrated faster reperfusion and improved right ventricular recovery, this 90-day data highlights significant patient centered benefits of CAVT in intermediate high risk PE,” said Robert...
“Together with the initial STORM PE results, which demonstrated faster reperfusion and improved right ventricular recovery, this 90-day data highlights significant patient centered benefits of CAVT in intermediate high risk PE,” said Robert...
iMRI enables a minimally invasive interventional practice ideal for precise soft tissue imaging, tumor targeting, biopsy and future ablation therapies, representing the future of radiation-free, image-guided care.
iMRI enables a minimally invasive interventional practice ideal for precise soft tissue imaging, tumor targeting, biopsy and future ablation therapies, representing the future of radiation-free, image-guided care.
NIH-sponsored C-TRACT Trial finds opportunity to treat often ignored DVT complication.
TORONTO (April 13, 2026)—The results of a prominent, National Institutes of Health (NIH) sponsored study into the treatment of post-thrombotic syndrome...
NIH-sponsored C-TRACT Trial finds opportunity to treat often ignored DVT complication.
TORONTO (April 13, 2026)—The results of a prominent, National Institutes of Health (NIH) sponsored study into the treatment of post-thrombotic syndrome...
Global pioneer of embolotherapy and leading U.S. interventional radiologist join forces with CUC America to build a scalable Office-Based Laboratory (OBL) platform
New Baltimore, MI — April 9, 2026 — CUC America, a leading provider of...
Global pioneer of embolotherapy and leading U.S. interventional radiologist join forces with CUC America to build a scalable Office-Based Laboratory (OBL) platform
New Baltimore, MI — April 9, 2026 — CUC America, a leading provider of...
CE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver disease
FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company)...
CE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver disease
FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company)...